Ofatumumab in AQP4-IgG Seropositive NMOSD

Exclusion Criteria

• •Progressive neurological deterioration unrelated to relapses of NMOSD, or presence of neurological findings suspected with PML.
• •Pregnant or breastfeeding patients and those with family planning during the study period.
• •Patients participating in any other clinical therapeutic study at the screening or within 30 days of screening.
• •Patients with splenectomy or history of no spleen, and those with planned surgery (excluding minor surgery) during the study period.
• •Presence of uncontrolled severe concurrent diseases; long-term glucocorticoids or immunosuppressants use due to other autoimmune diseases, or presence of other chronic diseases that cannot receiving immunosuppression.
• •Active infection at within 4 weeks before baseline.
• •Positive for HBV or HCV.
• •Evidence of latent or active tuberculosis (TB).
• •Have received any live or live-attenuated vaccine within 6 weeks before baseline.
• •History of malignancy in past 5 years, including solid tumor, malignant hematopathy and carcinoma in situ.
• •History of severe allergic reactions to biological agents.
• •Inability to provide written informed consent.